Alfalak Electronic Equipment & Supplies Co., a provider of technology-based end-to-end solutions in the Middle East, has partnered with Mariner and deployed xVu, Mariner’s award-winning IPTV service assurance platform.
Mariner’s xVu suite of service assurance products enables lower operating costs for TV service providers through effective trouble isolation and the avoidance of recurring field costs such as dispatches and truck rolls that are not necessary. Service providers have reduced upwards of 20% of truck rolls through the use of xVu.
“The incorporation of Mariner’s xVu into our IPTV solution will assist Alfalak in maintaining our leadership in IPTV and providing a superior solution to the region’s telecom providers,” states Ahmed Ashadawi, President Alfalak Electronic Equipment & Supplies. “The addition of a recognized quality assurance solution from Mariner is a solid complement to our growing list of partnerships in the delivery of unrivaled end-to-end solutions to our customers.”
“We believe that Alfalak is a valuable partner to enable the best support for our customers in the Middle-East,” states Curtis Howe, President and CEO of Mariner. “Their expertise in IPTV and widespread penetration in the Telecom market is a key asset for our growth in the region. We are pleased to welcome Alfalak as a local partner to offer a complete end-to-end IPTV service assurance solution.”
– Alfalak positions itself as the technology leader in IPTV and has extended support to the region’s telecom operators as they adapt their integration solutions to deliver video over IP – a process with requirements distinct from voice delivery over IP. Alfalak has signed several high-end contracts to provide Triple Play IPTV technology using PAL (MPEG-4) AVC H2.64 format.
– Alfalak delivers turnkey Triple Play IPTV for specific industries such as telecom, healthcare and hospitality solutions.
– Mariner’s xVu is currently deployed with service providers across Canada, the U.S., the Caribbean and the Asia-Pacific markets. The solution is also in lab trials with European service providers.